We propose a broad-based program to characterize in detail the replication of human immunodeficiency virus (HIV). Understanding of retroviral replication is key to the design of agents which can effectively intervene to prevent the devastating in vivo effects of viral replication. In this application a group of molecular and cell biologists will utilize expertise gained in other systems, including studies of avian and murine retroviral replication, oncogenesis, and gene expression, in order to achieve this goal. Specific approaches of the individual projects will be: 1. Identification of sequences required for HIV genomic packaging and development of packaging lines to deliver sequences to HIV target cells; 2. Detailed characterization of the processing of the HIV gag gene product and the role of the virally encoded protease in viral assembly; 3. Analysis of transcriptional termination in the HIV genome and the role of the tat gene product in this process; 4. Development of vectors containing antisense viral constructs for the inhibition of viral replication and the elucidation of the mechanism of antisense inhibition; 5. Molecular analysis of the sequences in cytomegalovirus (CMV) which activate HIV gene expression and determination as to whether reciprocal activation occurs; 6. Mutagenesis of the HIV genome in order to identify trans-acting dominant-negative mutants of HIV which could inhibit replication of wild-type HIV; 7. Analysis of whether HIV replication requires specific phases of the host cell cycle and which phases of HIV replication are cell-cycle dependent. These projects interdigitate in their use of common reagents and the generation of reagents and information necessary for the completion of the specific goals. Collectively, the investigators provide all of the technical expertise required for the successful attainment of the goals including cloning and sequencing, vector construction, cell culture and virus growth, protein analysis, in vitro and in vivo assay of transcription products, and cell cycle analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI027291-05
Application #
3091964
Study Section
Special Emphasis Panel (SRC (90))
Project Start
1988-09-01
Project End
1994-08-31
Budget Start
1992-09-01
Budget End
1994-08-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Harrington, R D; Geballe, A P (1996) Human immunodeficiency virus type-1 susceptible whole cell and microcell hybrids. Ann Clin Lab Sci 26:522-30
Geigenmuller, U; Linial, M L (1996) Specific binding of human immunodeficiency virus type 1 (HIV-1) Gag-derived proteins to a 5' HIV-1 genomic RNA sequence. J Virol 70:667-71
Lewis, P F; Emerman, M (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68:510-6
Garcia, J V; Miller, A D (1994) Retrovirus vector-mediated transfer of functional HIV-1 regulatory genes. AIDS Res Hum Retroviruses 10:47-52
To, R Y; Booth, S C; Turk, G et al. (1994) Completion of avian retroviral DNA replication intermediates inhibited by antisense RNA. Virology 200:336-46
Adams, M; Sharmeen, L; Kimpton, J et al. (1994) Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A 91:3862-6
Lee, P P; Linial, M L (1994) Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J Virol 68:6644-54
Garcia, J V; Alfano, J; Miller, A D (1993) The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4. J Virol 67:1511-6
Harrington, R D; Geballe, A P (1993) Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol 67:5939-47
Geballe, A P; Gray, M K (1992) Variable inhibition of cell-free translation by HIV-1 transcript leader sequences. Nucleic Acids Res 20:4291-7

Showing the most recent 10 out of 19 publications